Maria Alice V. Willrich, Ph.D.

  1. Chemist

Publications

  1. Acosta-Medina AA, Moyer AM, Go RS, Willrich MAV, Fervenza FC, Leung N, Bourlon C, Winters JL, Spears GM, Bryant SC, Sridharan M. Complement Gene Variant Effect on Relapse of Complement-Mediated Thrombotic Microangiopathy after Eculizumab Cessation. Blood Adv. 2022 May 9 Epub 2022 May 09
    View PubMed
  2. Saadeh RS, Bryant SC, McKeon A, Weinshenker B, Murray DL, Pittock SJ, Willrich MAV. CSF Kappa Free Light Chains: Cutoff Validation for Diagnosing Multiple Sclerosis. Mayo Clin Proc. 2022 Apr; 97 (4):738-751 Epub 2021 Dec 08
    View PubMed
  3. Dasari S, Kohlhagen MC, Dispenzieri A, Willrich MAV, Snyder MR, Kourelis TV, Lust JA, Mills JR, Kyle RA, Murray DL. Detection of Plasma Cell Disorders by Mass Spectrometry: A Comprehensive Review of 19,523 Cases. Mayo Clin Proc. 2022 Feb; 97 (2):294-307 Epub 2021 Dec 07
    View PubMed
  4. Willrich MAV. Commentary on Significance of Monoclonal Band in Cerebral Spinal Fluid. Clin Chem 2022 Feb 1; 68 (2):281
    View PubMed
  5. Willrich MAV, Braun KMP, Moyer AM, Jeffrey DH, Frazer-Abel A. Complement testing in the clinical laboratory. Crit Rev Clin Lab Sci. 2021 Nov; 58 (7):447-478 Epub 2021 May 07
    View PubMed
  6. Fatica EM, Martinez M, Ladwig PM, Murray JD, Kohlhagen MC, Kyle RA, Kourelis T, Lust JA, Snyder MR, Dispenzieri A, Murray DL, Willrich MAV. MALDI-TOF mass spectrometry can distinguish immunofixation bands of the same isotype as monoclonal or biclonal proteins. Clin Biochem. 2021 Nov; 97:67-73 Epub 2021 Aug 09
    View PubMed
  7. Mellors PW, Kohlhagen MC, Dasari S, Willrich MAV, Gertz MA, Kumar SK, Lacy MQ, Murray DL, Dispenzieri A. Belantamab mafodotin detection by MASS-FIX and immunofixation. Clin Chem Lab Med 2021 Oct 26; 59 (11):e430-e433 Epub 2021 June 11
    View PubMed
  8. Borren NZ, Paulides E, Frinack JL, Olson RN, Willrich MAV, van der Woude CJ, Ananthakrishnan AN. Infliximab Trough Levels Are Not Predictive of Relapse in Patients with IBD in Endoscopic Remission: A Multicenter Cohort Study. Dig Dis Sci. 2021 Oct; 66 (10):3548-3554 Epub 2020 Oct 10
    View PubMed
  9. Alrahmani L, Gonzalez Suarez ML, Cousin MA, Moyer AM, Willrich MAV, White WM, Wick MJ, Tostrud LJ, Narang K, Garovic VD. Quantitative Alterations in Complement Alternative Pathway and Related Genetic Analysis in Severe Phenotype Preeclampsia. Kidney360. 2021 Sep 30; 2 (9):1463-1472 Epub 2021 June 30
    View PubMed
  10. Knight V, Heimall JR, Chong H, Nandiwada SL, Chen K, Lawrence MG, Sadighi Akha AA, Kumanovics A, Jyonouchi S, Ngo SY, Vinh DC, Hagin D, Forbes Satter LR, Marsh RA, Chiang SCC, Willrich MAV, Frazer-Abel AA, Rider NL. A Toolkit and Framework for Optimal Laboratory Evaluation of Individuals with Suspected Primary Immunodeficiency. J Allergy Clin Immunol Pract. 2021 Sep; 9 (9):3293-3307.e6 Epub 2021 May 24
    View PubMed
  11. Fatica EM, Larkey NE, Gleue CA, Willrich MAV. A Case of Unexpected Hyperglycemia. Clin Chem. 2021 Aug 5; 67 (8):1056-1059
    View PubMed
  12. Ladwig PM, Willrich MAV. Ravulizumab: Characterization and quantitation of a new C5 inhibitor using isotype specific affinity purification and high-resolution mass spectrometry. J Mass Spectrom Adv Clin Lab. 2021 Aug; 21:10-18 Epub 2021 Aug 12
    View PubMed
  13. Graden KC, Bennett SA, Delaney SR, Gill HE, Willrich MAV. A High-Level Overview of the Regulations Surrounding a Clinical Laboratory and Upcoming Regulatory Challenges for Laboratory Developed Tests. Lab Med. 2021 Jul 1; 52 (4):315-328
    View PubMed
  14. Mellors PW, Dasari S, Kohlhagen MC, Kourelis T, Go RS, Muchtar E, Gertz MA, Kumar SK, Buadi FK, Willrich MAV, Lust JA, Kapoor P, Lacy MQ, Dingli D, Hwa Y, Fonder A, Hobbs M, Hayman S, Warsame R, Leung NR, Lin Y, Gonsalves W, Siddiqui M, Kyle RA, Rajkumar SV, Murray DL, Dispenzieri A. Correction: MASS-FIX for the detection of monoclonal proteins and light chain N-glycosylation in routine clinical practice: a cross-sectional study of 6315 patients. Blood Cancer J. 2021 Jun 7; 11 (6):110 Epub 2021 June 07
    View PubMed
  15. Kohlhagen MC, Mills JR, Willrich MAV, Dasari S, Dispenzieri A, Murray DL. Clearing drug interferences in myeloma treatment using mass spectrometry. Clin Biochem. 2021 Jun; 92:61-66 Epub 2021 Mar 07
    View PubMed
  16. Ramos GP, Al-Bawardy B, Braga MB, Bledsoe AC, Quinn KP, Heron V, Willrich, Johnson A, Chedid VG, Coelho-Prabhu N, Kisiel JB, Papadakis KA, Pardi D, Kane S, Tremaine WJ, Raffals L, Bruining DH, Faubion WA, Harmsen WS, Loftus EV Jr. Certolizumab trough levels and antibodies in Crohn disease: a single-center experience. Crohn's & Colitis 360. 2021; 3(3):1-8.
  17. Mellors PW, Dasari S, Kohlhagen MC, Kourelis T, Go RS, Muchtar E, Gertz MA, Kumar SK, Buadi FK, Willrich MAV, Lust JA, Kapoor P, Lacy MQ, Dingli D, Hwa Y, Fonder A, Hobbs M, Hayman S, Warsame R, Leung NR, Lin Y, Gonsalves W, Siddiqui M, Kyle RA, Rajkumar SV, Murray DL, Dispenzieri A. MASS-FIX for the detection of monoclonal proteins and light chain N-glycosylation in routine clinical practice: a cross-sectional study of 6315 patients. Blood Cancer J. 2021 Mar 4; 11 (3):50 Epub 2021 Mar 04
    View PubMed
  18. Willrich MAV, Ladwig PM, Martinez MA, Sridharan MR, Go RS, Murray DL, Complement Alternative Pathway Thrombotic Microangiopathy (CAP-TMA) Disease Oriented Group at the Mayo Clinic. Monitoring Ravulizumab effect on complement assays. J Immunol Methods. 2021 Mar; 490:112944 Epub 2020 Dec 13
    View PubMed
  19. Sadighi Akha AA, Tschumper RC, Mills JR, Isham CR, Witty EE, Viswanatha DS, Dasari S, Snyder MR, Murray DL, Katzmann JA, Jelinek DF, Willrich MAV. A rare case of selective Igkappa chain deficiency: Biologic and clinical implications. J Allergy Clin Immunol 2020 Nov; 146 (5):1208-1210.e6 Epub 2020 Apr 08
    View PubMed
  20. Sidana S, Murray DL, Dasari S, Go RS, Muchtar E, Willrich MA, Snyder M, Kohlhagen M, Lust JA, Kourelis TV, Kumar SK, Dispenzieri A, Gertz MA. Glycosylation of immunoglobulin light chains is highly prevalent in cold agglutinin disease. Am J Hematol 2020 Sep; 95 (9):E222-E225 Epub 2020 June 12
    View PubMed
  21. Kohlhagen M, Dasari S, Willrich M, Hetrick M, Netzel B, Dispenzieri A, Murray DL. Automation and validation of a MALDI-TOF MS (Mass-Fix) replacement of immunofixation electrophoresis in the clinical lab. Clin Chem Lab Med. 2020 Aug 3; 59 (1):155-163 Epub 2020 Aug 03
    View PubMed
  22. Cradic KW, Ladwig PM, Rivard AL, Katrangi W, Wintgens KF, Willrich MAV. Vedolizumab quantitation using high-resolution accurate mass-mass spectrometry middle-up protein subunit: method validation. Clin Chem Lab Med. 2020 Jun 25; 58 (6):864-872
    View PubMed
  23. Turner KA, Frinack JL, Ettore MW, Tate JR, Graziani MS, Jacobs JFM, Booth RA, McCudden CR, Keren DF, Delgado JC, Zemtsovskaja G, Fullinfaw RO, Caldini A, de Malmanche T, Katakouzinos K, Burke M, Palladini G, Altinier S, Zaninotto M, Righetti G, Melki MT, Bell S, Willrich MAV. An international multi-center serum protein electrophoresis accuracy and M-protein isotyping study. Part I: factors impacting limit of quantitation of serum protein electrophoresis. Clin Chem Lab Med. 2020 Mar 26; 58 (4):533-546
    View PubMed
  24. Jacobs JFM, Turner KA, Graziani MS, Frinack JL, Ettore MW, Tate JR, Booth RA, McCudden CR, Keren DF, Delgado JC, Zemtsovskaja G, Fullinfaw RO, Caldini A, de Malmanche T, Katakouzinos K, Burke M, Palladini G, Altinier S, Zaninotto M, Righetti G, Melki MT, Bell S, Willrich MAV. An international multi-center serum protein electrophoresis accuracy and M-protein isotyping study. Part II: limit of detection and follow-up of patients with small M-proteins. Clin Chem Lab Med. 2020 Mar 26; 58 (4):547-559
    View PubMed
  25. Park SH, Al-Bawardy B, Aniwan S, Kane SV, Coelho-Prabhu N, Papadakis KA, Kisiel JB, Bruining DH, Faubion WA, Raffals LE, Pardi DS, Tremaine WJ, Stephens MC, Tung J, Khanna S, Willrich, Loftus EV. Distinct cutoff values of adalimumab trough levels are associated with different therapeutic outcomes in patients with inflammatory bowel disease. Crohn's & Colitis 360. 2019; 1(3):otz047.
  26. Murray DL, Willrich MAV. Evolution of Myeloma Testing in Clinical Chemistry with Mass Spectrometry. J Appl Lab Med 2019 Nov; 4 (3):474-476
    View PubMed
  27. Turner KA, Eckelkamp LL, Kalass SJ, Martinez MA, Brewer HR, Hoyne JB, Snyder MR, Murray DL, Willrich MAV. Correlation Between Kappa Prozone Effect and IgA Kappa M Proteins in Serum Free Light-Chain Assay. Clin Chem 2019 Oct; 65 (10):1327-1329 Epub 2019 Aug 06
    View PubMed
  28. Sepiashvili L, Kohlhagen MC, Snyder MR, Willrich MAV, Mills JR, Dispenzieri A, Murray DL. Direct Detection of Monoclonal Free Light Chains in Serum by Use of Immunoenrichment-Coupled MALDI-TOF Mass Spectrometry. Clin Chem. 2019 Aug; 65 (8):1015-1022 Epub 2019 June 06
    View PubMed
  29. Al-Bawardy B, Ramos GP, Willrich MAV, Jenkins SM, Park SH, Aniwan S, Schoenoff SA, Bruining DH, Papadakis KA, Raffals L, Tremaine WJ, Loftus EV. Vedolizumab Drug Level Correlation With Clinical Remission, Biomarker Normalization, and Mucosal Healing in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2019 Feb 21; 25 (3):580-586
    View PubMed
  30. Willrich MAV. Analysis of Tryptic Peptides from Therapeutic Monoclonal Antibodies Using LC-MS/MS. Methods Mol Biol. 2019; 1872:85-99
    View PubMed
  31. Sridharan M, Go RS, Willrich MAV. Atypical hemolytic uremic syndrome: Review of clinical presentation, diagnosis and management. J Immunol Methods. 2018 Oct; 461:15-22 Epub 2018 July 19
    View PubMed
  32. Sridharan M, Go RS, Abraham RS, Fervenza FC, Sethi S, Bryant SC, Spears GM, Murray DL, Willrich MAV. Diagnostic Utility of Complement Serology for Atypical Hemolytic Uremic Syndrome. Mayo Clin Proc. 2018 Oct; 93 (10):1351-1362
    View PubMed
  33. Willrich MAV, Andreguetto BD, Sridharan M, Fervenza FC, Tostrud LJ, Ladwig PM, Rivard AM, Hetrick MD, Olson RN, Bryant SC, Snyder MR, Murray DL. The impact of eculizumab on routine complement assays. J Immunol Methods. 2018 Sep; 460:63-71 Epub 2018 June 20
    View PubMed
  34. Mills JR, Kohlhagen MC, Willrich MAV, Kourelis T, Dispenzieri A, Murray DL. A universal solution for eliminating false positives in myeloma due to therapeutic monoclonal antibody interference. Blood 2018 Aug 9; 132 (6):670-672 Epub 2018 June 11
    View PubMed
  35. Gurtner KM, Shosha E, Bryant SC, Andreguetto BD, Murray DL, Pittock SJ, Willrich MAV. CSF free light chain identification of demyelinating disease: comparison with oligoclonal banding and other CSF indexes. Clin Chem Lab Med. 2018 Jun 27; 56 (7):1071-1080
    View PubMed
  36. Alrahmani L, Willrich MAV. The Complement Alternative Pathway and Preeclampsia. Curr Hypertens Rep. 2018 May 1; 20 (5):40 Epub 2018 May 01
    View PubMed
  37. Willrich MAV, Lazar-Molnar E, Snyder MR, Delgado JC. Comparison of Clinical Laboratory Assays for Measuring Serum Infliximab and Antibodies to Infliximab. J Appl Lab Med. 2018 May 1; 2 (6):893-903
    View PubMed
  38. Willrich MAV, Murray DL, Kyle RA. Laboratory testing for monoclonal gammopathies: Focus on monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Clin Biochem. 2018 Jan; 51:38-47 Epub 2017 May 04
    View PubMed
  39. Willrich MAV. Therapeutic Monoclonal Antibodies in the Clinical Laboratory. J Appl Lab Med. 2017 Nov 1; 2 (3):454-457
    View PubMed
  40. Ladwig PM, Barnidge DR, Willrich MAV. Mass Spectrometry Approaches for Identification and Quantitation of Therapeutic Monoclonal Antibodies in the Clinical Laboratory. Clin Vaccine Immunol. 2017 May; 24 (5) Epub 2017 May 05
    View PubMed
  41. Ladwig PM, Barnidge DR, Willrich MA. Quantification of the IgG2/4 kappa Monoclonal Therapeutic Eculizumab from Serum Using Isotype Specific Affinity Purification and Microflow LC-ESI-Q-TOF Mass Spectrometry. J Am Soc Mass Spectrom. 2017 May; 28 (5):811-817 Epub 2016 Dec 21
    View PubMed
  42. Mills JR, Kohlhagen MC, Dasari S, Vanderboom PM, Kyle RA, Katzmann JA, Willrich MA, Barnidge DR, Dispenzieri A, Murray DL. Comprehensive Assessment of M-Proteins Using Nanobody Enrichment Coupled to MALDI-TOF Mass Spectrometry. Clin Chem. 2016 Oct; 62 (10):1334-44 Epub 2016 Aug 18
    View PubMed
  43. Go RS, Winters JL, Leung N, Murray DL, Willrich MA, Abraham RS, Amer H, Hogan WJ, Marshall AL, Sethi S, Tran CL, Chen D, Pruthi RK, Ashrani AA, Fervenza FC, Cramer CH 2nd, Rodriguez V, Wolanskyj AP, Thome SD, Hook CC, Mayo Clinic Complement Alternative Pathway-Thrombotic Microangiopathy Disease-Oriented Group. Thrombotic Microangiopathy Care Pathway: A Consensus Statement for the Mayo Clinic Complement Alternative Pathway-Thrombotic Microangiopathy (CAP-TMA) Disease-Oriented Group. Mayo Clin Proc. 2016 Sep; 91 (9):1189-211 Epub 2016 Aug 03
    View PubMed
  44. Mills JR, Cornec D, Dasari S, Ladwig PM, Hummel AM, Cheu M, Murray DL, Willrich MA, Snyder MR, Hoffman GS, Kallenberg CG, Langford CA, Merkel PA, Monach PA, Seo P, Spiera RF, St Clair EW, Stone JH, Specks U, Barnidge DR. Using Mass Spectrometry to Quantify Rituximab and Perform Individualized Immunoglobulin Phenotyping in ANCA-Associated Vasculitis. Anal Chem. 2016 Jun 21; 88 (12):6317-25 Epub 2016 June 03
    View PubMed
  45. Moyer AM, Saenger AK, Willrich M, Donato LJ, Baumann NA, Block DR, Botz CM, Khan MA, Jaffe AS, Hanson CA, Karon BS. Implementation of Clinical Decision Support Rules to Reduce Repeat Measurement of Serum Ionized Calcium, Serum Magnesium, and N-Terminal Pro-B-Type Natriuretic Peptide in Intensive Care Unit Inpatients. Clin Chem. 2016 Jun; 62 (6):824-30 Epub 2016 Mar 28
    View PubMed
  46. Willrich MA, Katzmann JA. Laboratory testing requirements for diagnosis and follow-up of multiple myeloma and related plasma cell dyscrasias. Clin Chem Lab Med. 2016 Jun 1; 54: (6)907-19.
    View PubMed
  47. Willrich MA, Ladwig PM, Andreguetto BD, Barnidge DR, Murray DL, Katzmann JA, Snyder MR. Monoclonal antibody therapeutics as potential interferences on protein electrophoresis and immunofixation. Clin Chem Lab Med. 2016 Jun 1; 54: (6)1085-93.
    View PubMed
  48. Tran CL, Sethi S, Murray D, Cramer CH, Sas DJ, Willrich M, Smith RJ, Fervenza FC. Discontinuation of dialysis with eculizumab therapy in a pediatric patient with dense deposit disease. Pediatr Nephrol. 2016 Apr; 31 (4):683-7 Epub 2016 Jan 13
    View PubMed
  49. Frazer-Abel A, Sepiashvili L, Mbughuni MM, Willrich MA. Overview of Laboratory Testing and Clinical Presentations of Complement Deficiencies and Dysregulation. Adv Clin Chem. 2016; 77:1-75.
    View PubMed
  50. Barnidge DR, Kohlhagen MC, Zheng S, Willrich MA, Katzmann JA, Pittock SJ, Murray DL. Monitoring oligoclonal immunoglobulins in cerebral spinal fluid using microLC-ESI-Q-TOF mass spectrometry. J Neuroimmunol. 2015 Nov 15; 288:123-6.
    View PubMed
  51. Willrich MA, Murray DL, Barnidge DR, Ladwig PM, Snyder MR. Quantitation of infliximab using clonotypic peptides and selective reaction monitoring by LC-MS/MS. Int Immunopharmacol. 2015 Sep; 28: (1)513-20.
    View PubMed
  52. Willrich MA, Wittwer CA, Willrich MA, Baumann NA, Block DR. A dark-brown serum sample. Clin Chem. 2015 Jul; 61 (7):999-1000
    View PubMed
  53. Willrich MA, Murray DL, Snyder MR. Tumor necrosis factor inhibitors: clinical utility in autoimmune diseases. Transl Res. 2015 Feb; 165 (2):270-82 Epub 2014 Sept 22
    View PubMed
  54. Katzmann JA, Willrich MA, Kohlhagen MC, Willrich MA, Kyle RA, Murray DL, Snyder MR, Rajkumar SV, Dispenzieri A. Monitoring IgA multiple myeloma: immunoglobulin heavy/light chain assays. Clin Chem. 2015 Feb; 61 (2):360-7 Epub 2014 Dec 01
    View PubMed
  55. Barnidge DR, Dasari S, Ramirez-Alvarado M, Fontan A, Willrich MA, Tschumper RC, Jelinek DF, Snyder MR, Dispenzieri A, Katzmann JA, Murray DL. Phenotyping polyclonal kappa and lambda light chain molecular mass distributions in patient serum using mass spectrometry. J Proteome Res. 2014 Nov 7; 13(11):5198-205. Epub 2014 Aug 26.
    View PubMed
  56. Willrich MA, Murray DL, Snyder MR. Tumor necrosis factor inhibitors: clinical utility in autoimmune diseases. Transl Res [Review]. 2014 Sep 22.
  57. Barnidge D, Dasari S, Ramirez-Alvarado M, Fontan A, Willrich M, Tschumper R, et al. Quantifying Polyclonal Kappa and Lambda Light Chain Molecular Mass Distributions by Mass Spectrometry. Journal of Proteome Research [Original Research] 14. 2014.
  58. Willrich MA, Baudhuin LM. PCSK9 and the road less traveled: how an unconventional approach led to a major discovery. Clin Chem 2013 Aug; 59 (8):1283-4
    View PubMed
  59. Willrich MA, Rodrigues AC, Cerda A, Genvigir FD, Arazi SS, Dorea EL, Bernik MM, Bertolami MC, Faludi A, Largura A, Baudhuin LM, Bryant SC, Hirata MH, Hirata RD. Effects of atorvastatin on CYP3A4 and CYP3A5 mRNA expression in mononuclear cells and CYP3A activity in hypercholeresterolemic patients. Clin Chim Acta. 2013 Jun 5; 421:157-63. Epub 2013 Mar 15.
    View PubMed
  60. Rodrigues AC, Sobrino B, Genvigir FD, Willrich MA, Arazi SS, Dorea EL, et al. Genetic variants in genes related to lipid metabolism and atherosclerosis, dyslipidemia and atorvastatin response. Clin Chim Acta. 2013 Feb 18; 417:8-11.
  61. Rodrigues AC, Sobrino B, Genvigir FD, Willrich MA, Arazi SS, Dorea EL, et al. Genetic variants in genes related to lipid metabolism and atherosclerosis, dyslipidemia and atorvastatin response. Clin Chim Acta. 2012 Dec 13; 417C:8-11.
  62. Silbiger VN, Hirata MH, Luchessi AD, Genvigir FD, Cerda A, Rodrigues AC, et al. Differentiation of African components of ancestry to stratify groups in a case-control study of a Brazilian urban population. Genet Test Mol Biomarkers. 2012 Jun; 16(6):524-30.
  63. Rodrigues AC, Perin PM, Purim SG, Silbiger VN, Genvigir FD, Willrich MA, et al. Pharmacogenetics of OATP Transporters Reveals That SLCO1B1 c. 388A>G Variant Is Determinant of Increased Atorvastatin Response Int J Mol Sci. 2011; 12(9):5815-27.
  64. Cerda A, Genvigir FD, Willrich MA, Arazi SS, Bernik MM, Dorea EL, et al. Apolipoprotein E mRNA expression in mononuclear cells from normolipidemic and hypercholesterolemic individuals treated with atorvastatin. Lipids Health Dis. 2011; 10:206.
  65. Cerda A, Genvigir FD, Rodrigues AC, Willrich MA, Dorea EL, Bernik MM, et al. Influence of polymorphisms and cholesterol-lowering treatment on SCARB1 mRNA expression. J Atheroscler Thromb. 2011; 18(8):640-51.
  66. Genvigir FD, Rodrigues AC, Cerda A, Arazi SS, Willrich MA, Oliveira R, et al. Effects of lipid-lowering drugs on reverse cholesterol transport gene expressions in peripheral blood mononuclear and HepG2 cells. Pharmacogenomics. 2010 Sep; 11(9):1235-46.
  67. Willrich MA, Hirata MH, Hirata RD. Statin regulation of CYP3A4 and CYP3A5 expression. Pharmacogenomics. 2009 Jun; 10(6):1017-24.
  68. Rebecchi IM, Rodrigues AC, Arazi SS, Genvigir FD, Willrich MA, Hirata MH, et al. ABCB1 and ABCC1 expression in peripheral mononuclear cells is influenced by gene polymorphisms and atorvastatin treatment. Biochem Pharmacol 1. 2009 Jan 1; 77(1):66-75.
  69. Willrich MA, Hirata MH, Genvigir FD, Arazi SS, Rebecchi IM, Rodrigues AC, et al. CYP3A53A allele is associated with reduced lowering-lipid response to atorvastatin in individuals with hypercholesterolemia. Clin Chim Acta. 2008 Dec; 398(1-2):15-20.
  70. Arazi SS, Genvigir FD, Willrich MA, Hirata MH, Dorea EL, Bernik M, et al. Atorvastatin effects on SREBF1a and SCAP gene expression in mononuclear cells and its relation with lowering-lipids response. Clin Chim Acta. 2008 Jul 17; 393(2):119-24.
  71. Genvigir FD, Soares SA, Hirata MH, Willrich MA, Arazi SS, Rebecchi IM, et al. Effects of ABCA1 SNPs, including the C-105T novel variant, on serum lipids of Brazilian individuals. Clin Chim Acta. 2008 Mar; 389(1-2):79-8.
  72. Silva FR, Szpoganicz B, Pizzolatti MG, Willrich MA, de Sousa E. Acute effect of Bauhinia forficata on serum glucose levels in normal and alloxan-induced diabetic rats. J Ethnopharmacol. 2002 Nov; 83(1-2):33-7.
PST-20514415